A previous study had shown that the overexpression of ST6GAL1 strongly inhibits monocyte-transendothelial migration, suggesting that ST6GAL1 could be a potential target for atherosclerosis prevention and treatment (67). This evidence concerns the gene ST6GAL1 and atherosclerosis.